Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strain Study initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study in seasonal ...
CureVac N.V. ( NASDAQ:CVAC ) just released its latest quarterly report and things are not looking great. It was a...
CureVac ( NASDAQ:CVAC ) First Quarter 2024 Results Key Financial Results Revenue: €12.4m (up 74% from 1Q 2023). Net...